Cargando…

Therapy-related B-lymphoblastic leukemia after multiple myeloma

New therapies for multiple myeloma have improved outcomes, but are associated with therapy-related hematologic malignancies. We report eight patients with therapy-related B-lymphoblastic leukemias (t-B-ALL) in the setting of therapy for multiple myeloma, which included lenalidomide maintenance. A su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kallen, Michael E., Koka, Rima, Singh, Zeba N., Ning, Yi, Kocoglu, Mehmet H., Badros, Ashraf Z., Niyongere, Sandrine, Duong, Vu H., Emadi, Ashkan, Baer, Maria R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637917/ https://www.ncbi.nlm.nih.gov/pubmed/36353199 http://dx.doi.org/10.1016/j.lrr.2022.100358

Ejemplares similares

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
por: Niyongere, Sandrine, et al.
Publicado: (2020)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era
por: Rybinski, Brad, et al.
Publicado: (2022)

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
por: Mustafa Ali, Moaath K., et al.
Publicado: (2022)

Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
por: Corley, Elizabeth M., et al.
Publicado: (2022)

Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
por: Corley, Elizabeth M., et al.
Publicado: (2022)

Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target
por: Holtzman, Noa G., et al.
Publicado: (2021)

Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study
por: Rybinski, Brad, et al.
Publicado: (2021)

Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia
por: Koka, Rima, et al.
Publicado: (2017)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia
por: Gudipati, Mary, et al.
Publicado: (2023)

Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia
por: Emadi, Ashkan, et al.
Publicado: (2016)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
por: Patzke, Ciera L., et al.
Publicado: (2020)

Multiple myeloma secondary to acute lymphoblastic leukemia: A case report
por: Hu, Tonglin, et al.
Publicado: (2019)

Chronic myeloid leukemia presenting as an atraumatic splenic rupture in the setting of coronavirus disease 2019 infection
por: Alharthy, Hanan, et al.
Publicado: (2023)

Promyelocytic sarcoma of the right humerus: an unusual clinical presentation with unique diagnostic and treatment considerations
por: Sawhney, Sameer, et al.
Publicado: (2017)

Acute B Lymphoblastic Leukemia Developing in Patients with Multiple Myeloma: Presentation of Two Cases
por: Mei, Jiang, et al.
Publicado: (2019)

1-C Metabolism—Serine, Glycine, Folates—In Acute Myeloid Leukemia
por: Mahmood, Kanwal, et al.
Publicado: (2021)

The effect of resveratrol on the expression of MDR1 gene in leukemic lymphoblast’s of acute lymphoblastic leukemia patients
por: Hosein poor Feyzi, Abbas Ali, et al.
Publicado: (2015)

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
por: Badros, A Z, et al.
Publicado: (2013)

Reverse Pseudohyperkalemia: An Important Clinical Entity in Chronic Lymphocytic Leukemia
por: Mansoor, Sahar, et al.
Publicado: (2015)

Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report
por: Khan, Dr. Saqib Raza, et al.
Publicado: (2022)

Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression
por: Badros, Ashraf Z., et al.
Publicado: (2021)

Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics
por: Lee, Michelle H., et al.
Publicado: (2019)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report
por: Li, Junxun, et al.
Publicado: (2016)

The influence of NUDT15 variants on 6-mercaptopurine-induced neutropenia in Vietnamese pediatric acute lymphoblastic leukemia
por: Nguyen, Mai-Lan, et al.
Publicado: (2023)

FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
por: Li, Andrew Y., et al.
Publicado: (2021)

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
por: Ching, Travers, et al.
Publicado: (2020)

Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma
por: Lee, Hye-Young, et al.
Publicado: (2019)

Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
por: Khan, Abdullah M., et al.
Publicado: (2018)

Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance
por: Liu, Junru, et al.
Publicado: (2023)

Secondary acute lymphoblastic leukaemia in a multiple myeloma patient
por: Piszcz, Jaroslaw, et al.
Publicado: (2013)

Corrigendum to “Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features”
por: Khan, Abdullah M., et al.
Publicado: (2019)

Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma
por: Crosby, James, et al.
Publicado: (2022)

Acute lymphoblastic leukemia
por: Schrappe, Martin
Publicado: (2018)

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

Profound leukemia cutis in a patient with relapsed T-cell acute lymphoblastic leukemia
por: Nohria, Ambika, et al.
Publicado: (2021)

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study
por: Boissel, Nicolas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vmeab6g6rkokq8ii6jis41coif